(S)-Hexan-3-amine | 70218-55-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-Hexan-3-amine
• 英文别名: (3S)-hexan-3-amine
• CAS: 70218-55-2
• 化学式: C₆H₁₅N
• 分子量: 101.192
• InChiKey: HQLZFBUAULNEGP-LURJTMIESA-N

物化性质

• 沸点：
  119.3±8.0 °C(Predicted)
• 密度：
  0.768±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (S)-Hexan-3-amine 、 (1R,2S,5R)-Menthyl chloroformate 在 三乙胺 作用下， 以 乙醚 为溶剂， 生成 (1R,2S,5R)-2-isopropyl-5-methylcyclohexyl ((S)-hexan-3-yl)carbamate
  参考文献：
  名称：

  Synthesis of chiral primary amines: diastereoselective alkylation of N-[(1E)-alkylidene]-3,5-bis[(1S)-1-methoxyethyl]-4H-1,2,4-triazol-4-amines and N4–Nexocyclic bond cleavage in the resulting 1,2,4-triazol-4-alkylamines

  摘要：

  Enantiomerically pure 3,5-bis[(1S)-1-methoxyethyl]-4H-1,2,4-triazol-4-amine 14a and 3,5-bis[(1S)-1-ethoxyethyl]-4H-1,2,4-triazol-4-amine 14b were used as chiral auxiliaries to obtain enantiomerically enriched alpha-aminoacetals, primary alkyl and arylalkyl amines (ee ranging from 40% to 90%). The different stages of the process were imine formation from the corresponding aldehydes, diastereoselective addition of a Grignard reagent, quaternization of the triazole auxiliary and cleavage of the N-4-N-exocylic bond by LiBH4. The mechanism of the cleavage of the N-4-N-exocyclic bond is supported by the use of deuterated metal hydride. The absolute configurations of the new stereogenic centres were established by X-ray analyses of the enantiomerically pure stereomers isolated by semi-preparative liquid chromatography on a chiral support. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2008.12.015
• 作为产物：
  描述：

  在 锂硼氢 、 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 生成 (S)-Hexan-3-amine 、 1-benzyl-3,5-bis[(1S)-1-methoxyethyl]-4H-1,2,4-triazole
  参考文献：
  名称：

  Synthesis of chiral primary amines: diastereoselective alkylation of N-[(1E)-alkylidene]-3,5-bis[(1S)-1-methoxyethyl]-4H-1,2,4-triazol-4-amines and N4–Nexocyclic bond cleavage in the resulting 1,2,4-triazol-4-alkylamines

  摘要：

  Enantiomerically pure 3,5-bis[(1S)-1-methoxyethyl]-4H-1,2,4-triazol-4-amine 14a and 3,5-bis[(1S)-1-ethoxyethyl]-4H-1,2,4-triazol-4-amine 14b were used as chiral auxiliaries to obtain enantiomerically enriched alpha-aminoacetals, primary alkyl and arylalkyl amines (ee ranging from 40% to 90%). The different stages of the process were imine formation from the corresponding aldehydes, diastereoselective addition of a Grignard reagent, quaternization of the triazole auxiliary and cleavage of the N-4-N-exocylic bond by LiBH4. The mechanism of the cleavage of the N-4-N-exocyclic bond is supported by the use of deuterated metal hydride. The absolute configurations of the new stereogenic centres were established by X-ray analyses of the enantiomerically pure stereomers isolated by semi-preparative liquid chromatography on a chiral support. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2008.12.015

文献信息

• [EN] PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS<br/>[FR] DÉRIVÉS DE PYRIMIDINE POUR LE TRAITEMENT DE L'ASTHME, DE LA BRONCHO-PNEUMOPATHIE CHRONIQUE OBSTRUCTIVE (COPD), DE LA RHINITE ALLERGIQUE, DE LA CONJONCTIVITE ALLERGIQUE, DE LA DERMATITE ATOPIQUE, DU CANCER, DE L'HÉPATITE B, DE L'HÉPATITE C, DU VIH, DU
  申请人：ASTRAZENECA AB

  公开号：WO2009067081A1

  公开（公告）日：2009-05-28

  The present invention provides compounds of formula (I) wherein R 1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）中的化合物，其中R1、R2、R3和R4如规范中定义，以及其药用盐，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的应用。
• [EN] AMINOALKOXYPHENYL COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] COMPOSÉS AMINOALCOXYPHÉNYLE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2012067269A1

  公开（公告）日：2012-05-24

  The invention concerns compounds of Formula (I): (I) wherein n, m, p, R1 and R2 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful in the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.

  这项发明涉及式(I)的化合物：(I) 其中n、m、p、R1和R2如描述中所定义。本发明还涉及制备这些化合物的过程，用于制备这些化合物的新型中间体，含有它们的药物组合物以及它们在治疗疾病（例如癌症）中的用途。
• [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021154663A1

  公开（公告）日：2021-08-05

  Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

  根据公式I，化合物可用作Toll样受体7（TLR7）的激动剂。这些化合物可用于癌症治疗，特别是与抗癌免疫疗法药物结合使用，或作为疫苗佐剂。
• [EN] BENZYLAMINE COMPOUNDS AS TOLL -LIKE RECEPTOR 7 AGONISTS<br/>[FR] COMPOSÉS DE BENZYLAMINE À TITRE D'AGONISTES DU RÉCEPTEUR TOLL-LIKE 7
  申请人：ASTRAZENECA AB

  公开号：WO2012066336A1

  公开（公告）日：2012-05-24

  The invention concerns compounds of Formula (I), and pharmaceutically acceptable salts thereof: where such compounds act as TLR7 agonists and at the same time show advantageous selectivity over TLR8 and hERG, wherein the variable groups R1, R2 and n are as defined herein. The invention also relates to methods for the preparation of such compounds and intermediates useful in the preparation thereof, to pharmaceutical compositions containing such compounds, to the use of such compounds in the preparation of medicaments, and to the use of such compounds in the treatment of conditions mediated by TLR7, such as allergic diseases, autoimmune diseases, viral diseases and, in particular, cancer.

  该发明涉及式（I）的化合物及其药用盐：其中这些化合物作为TLR7激动剂，同时在TLR8和hERG上表现出有利的选择性，其中变量基团R1、R2和n如本文所定义。该发明还涉及制备这种化合物的方法和在制备中有用的中间体，含有这种化合物的药物组合物，利用这种化合物制备药物以及利用这种化合物治疗由TLR7介导的疾病，如过敏性疾病、自身免疫疾病、病毒性疾病，特别是癌症。
• [EN] CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] COMPOSÉS D'AMIDES CYCLIQUES ET LEUR UTILISATION DANS LE TRAITEMENT DE LA MALADIE
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2012067268A1

  公开（公告）日：2012-05-24

  The invention concerns compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein n, R1 and R2 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, novel intermediates useful in the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment of disease, for example cancer.

  该发明涉及式(I)的化合物和其药用可接受盐，其中n、R1和R2如描述中所定义。本发明还涉及制备这种化合物的方法，用于制备这种化合物的新型中间体，含有它们的药物组合物以及它们在疾病治疗中的应用，例如癌症。